bluebird bio prices upsized IPO above the range at $17

By
A A A

bluebird bio, a clinical-stage biotech developing gene therapies for severe genetic and orphan diseases, raised $101 million by offering 5.9 million shares at $17, above the range of $14 to $16. The company had originally planned to offer 5.0 million shares. bluebird bio will list on the NASDAQ under the symbol BLUE. bluebird bio initially filed confidentially on 3/21/2013. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: BLUE

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Living the Life of Pie
Living the Life of Pie              

Stocks

Referenced

Most Active by Volume

4,255,298
  • $15.26 ▼ 2.18%
2,398,760
  • $94.015 ▼ 1.44%
1,727,665
  • $93.72 ▼ 1.31%
1,726,516
  • $63.23 ▼ 2.68%
1,637,642
  • $3.3199 ▼ 0.90%
1,628,139
  • $26.14 ▼ 0.68%
1,370,006
  • $41.30 ▼ 0.89%
1,322,758
  • $3.46 ▼ 4.42%
As of 7/10/2014, 09:32 AM